(2) The extent of decrease of serum hepcidin levels was a strong predictor of symptom improvement in a dose-dependent manner after 12 weeks of dopaminergic treatment, independent of age, sex, CRP, sleep quality, insomnia, daytime sleepiness, depression and anxiety. The gene discussed is HAMP; the disease is insomnia.